Indeed, there are several ongoing clinical trials currently evaluating BET inhibitors in combination with azacitidine, daratumumab, entinostat, exemestane, fulvestrant, molibresib, rituximab, ruxolitinib, and venetoclax for the treatment of hematological malignancies (Table 1 and Table 2). Here, DNER is linked to hematologic disorder.